Skip to main content

Immunologic Factors clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • Cell therapy to Treat Patients with COVID-19

    open to eligible people ages 18 years and up

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    Sacramento, California and other locations

Last updated: